Targets › BTLA
2 programs from 2 companies in 2 trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Jan 2027.
Inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2. May interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14. (UniProt, Q7Z6A9)
Open in Phaseline: the race on BTLA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Junshi Bioscience Co., Ltd. | Tifcemalimab BTLA inhibitor (monoclonal antibody) | BTLA | Phase 3 | Limited-stage Small Cell Lung Cancer (LS-SCLC) | Jul 2027 |
| Shanghai Pulmonary Hospital, Shanghai, China | JS004 (tifcemalimab) BTLA inhibitor antibody | BTLA | Phase 2 | Limited Stage Small Cell Lung Cancer | Jan 2027 |
Limited-stage Small Cell Lung Cancer (LS-SCLC) (1) Limited Stage Small Cell Lung Cancer (1)
antibody (1), mixed (1)
Shanghai Junshi Bioscience Co., Ltd. (1) Shanghai Pulmonary Hospital, Shanghai, China (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.